NCT06636760

Efficacy and Immunomodulator Impact of Herbal Combination on COVID-19 Patients Recovery

Efficacy and Safety of Herbal Combination As Adjuvant Therapy for Mild and Moderate COVID-19 Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Indonesia University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of Herbamuno+, a combination of several herbal ingredients, as an adjunct therapy for moderate COVID-19 patients at Wisma Atlet. The study involves 66 patients who were divided into two groups: one receiving Herbamuno+ and the other a placebo, both for 14 days. Researchers monitored clinical improvements, chest X-rays, and blood tests to assess inflammation and immune response. The goal is to determine whether Herbamuno+ can be safely and effectively added to standard COVID-19 treatment.

Conditions

• COVID 19

Interventions

Type	Name	Description
OTHER	Placebo	The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
DIETARY_SUPPLEMENT	herbal compound	The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.

Timeline

• Start date: 2021-08-27
• Primary completion: 2022-03-28
• Completion: 2022-03-28
• First posted: 2024-10-15
• Last updated: 2024-10-15

Locations

1 site across 1 country: Indonesia